4D Molecular Therapeutics, Inc.

NasdaqGS FDMT

4D Molecular Therapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 341.41 M

4D Molecular Therapeutics, Inc. Net Cash Used Provided By Financing Activities is USD 341.41 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 121.53% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

4D Molecular Therapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 154.12 M, a 31.52% change year over year.
4D Molecular Therapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 117.18 M, a -43.64% change year over year.
4D Molecular Therapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 207.93 M, a 187.45% change year over year.
4D Molecular Therapeutics, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 72.33 M, a 77.49% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: FDMT

4D Molecular Therapeutics, Inc.

CEO	Dr. David H. Kirn M.D.
IPO Date	Dec. 11, 2020
Location	United States
Headquarters	5858 Horton Street
Employees	147
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Key trends

Past 5 years